NSCLC
3 competing products in clinical development for NSCLC.
Pipeline by Phase
Phase 11
Phase 1/21
Phase 31
All Products (3)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/Carboplatin | WuXi Biologics | Phase 3 | Completed | 74 |
| BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta) | BioAtla | Phase 1/2 | Active | 33 |
| BBP-398 + osimertinib | LianBio | Phase 1 | Terminated | 25 |